Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

被引:110
作者
Burdelya, L
Kujawski, M
Niu, GL
Zhong, B
Wang, TH
Zhang, SM
Kortylewski, A
Shain, K
Kay, H
Djeu, J
Dalton, W
Pardoll, D
Wei, S
Yu, H
机构
[1] H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Oncol, Coll Med, Tampa, FL 33612 USA
[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[4] Univ S Florida, Coll Publ Hlth, Tampa, FL 33612 USA
关键词
D O I
10.4049/jimmunol.174.7.3925
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infiltration of immune elfector cells in tumors is critical for antitumor immune responses. However, what regulates immune cell infiltration of tumors remains to be identified. Stat3 is constitutively activated with high frequency in diverse cancers, promoting tumor cell growth and survival. Blocking Stat3 signaling in tumors in vivo results in tumor growth inhibition that involves killing of nontransfected tumor cells and infiltration of immune effector cells, suggesting that Stat3 activity in tumor cells might affect immune cell recruitment. However, dying tumor cells can also attract immune cells. In this study, we show in isogenic murine melanomas that natural Stat3 activity is associated with tumor growth and reduction of T cell infiltration. Blocking Stat3 signaling in the melanoma cells containing high Stat3 activity results in expression of multiple chemoattractants, leading to increased migration of lymphocytes, NK cells, neutrophils, and macrophages. In addition, blocking Stat3 triggers tumor cells to produce soluble factors capable of activating macrophage production of NO in vitro and in vivo. TNF-alpha and IFN-beta, which are secreted by Stat3-inhibited tumor cells, are able to activate macrophage NO production, whereas neutralizing TNF-alpha in the tumor supernatant from Stat3-blocked tumor cells abrogates nitrite production. Moreover, interrupting Stat3 signaling in tumor cells leads to macrophage-mediated, nitrite-dependent cytostatic activity against nontransduced tumor cells. These results suggest that tumor Stat3 activity affects recruitment of diverse immune effectors and it can be manipulated to activate the effector phase of innate immune responses.
引用
收藏
页码:3925 / 3931
页数:7
相关论文
共 40 条
  • [1] Cancer immunotherapy: A treatment for the masses
    Blattman, JN
    Greenberg, PD
    [J]. SCIENCE, 2004, 305 (5681) : 200 - 205
  • [2] Bouvet M, 1998, CANCER RES, V58, P2288
  • [3] Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
    Bowman, T
    Broome, MA
    Sinibaldi, D
    Wharton, W
    Pledger, WJ
    Sedivy, JM
    Irby, R
    Yeatman, T
    Courtneidge, SA
    Jove, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) : 7319 - 7324
  • [4] STATs in oncogenesis
    Bowman, T
    Garcia, R
    Turkson, J
    Jove, R
    [J]. ONCOGENE, 2000, 19 (21) : 2474 - 2488
  • [5] Buettner R, 2002, CLIN CANCER RES, V8, P945
  • [6] Chemokines in the systemic organization of immunity
    Campbell, DJ
    Kim, CH
    Butcher, EC
    [J]. IMMUNOLOGICAL REVIEWS, 2003, 195 : 58 - 71
  • [7] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115
  • [8] A critical role for stat3 signaling in immune tolerance
    Cheng, FD
    Wang, HW
    Cuenca, A
    Huang, M
    Ghansah, T
    Brayer, J
    Kerr, WG
    Takeda, K
    Akira, S
    Schoenberger, SP
    Yu, H
    Jove, R
    Sotomayor, EM
    [J]. IMMUNITY, 2003, 19 (03) : 425 - 436
  • [9] Mutational switch of an IL-6 response to an interferon-γ-like response
    Costa-Pereira, AP
    Tininini, S
    Strobl, B
    Alonzi, T
    Schlaak, JF
    Is'harc, H
    Gesualdo, I
    Newman, SJ
    Kerr, IM
    Poli, V
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) : 8043 - 8047
  • [10] Transcription factors as targets for cancer therapy
    Darnell, JE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 740 - 749